CD274 and non-small cell lung carcinoma: In this proof-of-concept, prospective longitudinal observational study, we demonstrated that NSCLC patients treated with anti-PD-1/PD-L1 showed worse survival outcomes if they had a low baseline level of circulating NK cells.